Given Imaging launches trial for colonoscopy alternative

The PillCam Colon trial will encompass 800 patients who are at average risk for colonic polyps.

Capsule endoscopy company Given Imaging Ltd. (Nasdaq: GIVN; TASE:GIVN) reported today that it has initiated its first trial of PillCam Colon 2. The capsule will be tested in a large, multi-center pivotal study, ahead of an application to the US Food and Drug Administration (FDA).

800 patients, aged 50-75 years, who are at average risk for colonic polyps and comprise the normal screening population will be recruited by Given Imaging at 17 locations.

Prof. Douglas Rex of Indiana University School of Medicine, and Director of Endoscopy, Indiana University Hospital said, "While colonoscopy remains the most effective test for colorectal cancer screening, not everyone is willing to undergo colonoscopy. Only half of eligible Americans have had a screening test, so we welcome additional tools that can help us increase compliance and lower the incidence of colorectal cancer."

He added, "We recently completed a survey demonstrating that patients who are noncompliant with their physician's recommendation for a colonoscopy for colorectal cancer screening would prefer PillCam COLON capsule endoscopy over other screening modalities. Aspects of PillCam that are attractive include that it's less invasive, detects polyps better than some of the alternative tests and does not require either sedation or a driver to accompany the patient."

Given Image's share was down 1.11% on Nasdaq in afternoon trading today to $21.30, giving a market cap of $639.58 million.

Published by Globes, Israel business news - www.globes-online.com - on June 6, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס